Charles K Gayer Biocryst Pharmaceuticals Inc (BCRX) insider trading activity

Charles K Gayer is President and CCO of BIOCRYST PHARMACEUTICALS INC. Currently has a direct ownership of 952,583 shares of BCRX, which is worth approximately $6.74 Million. The most recent transaction as insider was on Dec 22, 2025, when has been sold 74,233 shares (Common Stock) at a price of $4.59 per share, resulting in proceeds of $340,729. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 953K

124.91% 3M change

124.91% 12M change

Total Value Held $6.74 Million

Charles K Gayer Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 22 2025	BUY Exercise of conversion of derivative security	$340,729 $4.59 p/Share	74,233 Added 7.23%	952,583 Common Stock
Dec 19 2025	SELL Payment of exercise price or tax liability	$85,044 $7.41 p/Share	11,477 Reduced 1.29%	878,350 Common Stock
Dec 17 2025	BUY Grant, award, or other acquisition	-	471,000 Added 34.61%	889,827 Common Stock
Dec 12 2025	SELL Payment of exercise price or tax liability	$61,930 $7.57 p/Share	8,181 Reduced 1.92%	418,827 Common Stock
Dec 19 2024	SELL Payment of exercise price or tax liability	$18,186 $7.39 p/Share	2,461 Reduced 0.58%	423,546 Common Stock
Dec 19 2024	BUY Grant, award, or other acquisition	-	125,950 Added 22.82%	426,007 Common Stock
Dec 14 2024	SELL Payment of exercise price or tax liability	$62,130 $7.53 p/Share	8,251 Reduced 2.68%	300,057 Common Stock

May 13 2024	BUY Open market or private purchase	$164,100 $5.47 p/Share	30,000 Added 8.89%	307,533 Common Stock
Dec 19 2023	SELL Payment of exercise price or tax liability	$15,016 $6.05 p/Share	2,482 Reduced 0.9%	274,533 Common Stock
Dec 14 2023	SELL Payment of exercise price or tax liability	$37,551 $6.43 p/Share	5,840 Reduced 2.06%	277,015 Common Stock
Dec 14 2023	BUY Grant, award, or other acquisition	-	34,000 Added 10.73%	282,855 Common Stock
Dec 19 2022	BUY Grant, award, or other acquisition	-	34,000 Added 12.16%	245,610 Common Stock
Dec 15 2022	SELL Open market or private sale	$66,490 $10.9 p/Share	6,100 Reduced 2.8%	211,610 Common Stock
Dec 14 2021	BUY Grant, award, or other acquisition	-	125,000 Added 32.34%	261,556 Common Stock

CKG

Charles K Gayer

President and CCO

Durham, NC

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells BCRX shares.

Notify only if

Value

Insider Trading

Get notified when an Biocryst Pharmaceuticals Inc insider buys or sells BCRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to BIOCRYST PHARMACEUTICALS INC

Track Activities on BCRX

Account